Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Dr Lombardi on Phase 1 Data With Regorafenib Plus Temozolomide and CRT for Newly Diagnosed Glioblastoma

November 22nd 2025

Giuseppe Lombardi, MD, PhD, discusses data with regorafenib plus temozolomide and radiation in newly diagnosed, MGMT-methylated, IDH-wild-type glioblastoma.

Dr Hirbe on Long-Term Efficacy and Safety Outcomes With Mirdametinib in Symptomatic NF1-PN

November 22nd 2025

Angela C. Hirbe, MD, PhD, discusses long-term follow-up data from the phase 2b ReNeu trial evaluating mirdametinib in patients with NF1-associated symptomatic PN.

Regorafenib Plus Temozolomide and RT Shows Early Signs of Tolerability in MGMT-Methylated, IDH Wild-Type Glioblastoma

November 22nd 2025

The RP2D of regorafenib when given with temozolomide and radiotherapy in patients with MGMT-methylated, IDH wild-type glioblastoma was 120 mg.

Vorasidenib Plus Temozolomide Demonstrates Safety in IDH1/2+ Glioma

November 22nd 2025

Vorasidenib plus temozolomide was safe in glioma harboring IDH1/2 mutations.

Dr Smith on the Role of Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

November 21st 2025

Matthew R. Smith, MD, PhD, discusses the role of darolutamide in mHSPC following its approval as monotherapy.

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

November 21st 2025

The FDA has approved neoadjuvant/adjuvant enfortumab vedotin plus pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer.

NDA for Zipalertinib in Pretreated NSCLC With EGFR Exon 20 Insertion Mutations Is Submitted to the FDA

November 21st 2025

A rolling NDA submission for zipalertinib in NSCLC with EGFR exon 20 insertion mutations who received prior chemotherapy has been initiated.

FDA Accepts NDA for Zidesamtinib in ROS1+ Advanced NSCLC After a Prior TKI

November 21st 2025

Will the FDA approve zidesamtinib for ROS1-positive advanced non–small cell lung cancer after a prior TKI?

CELMoDs Aim to Build on Established IMiDs in Multiple Myeloma Management

November 21st 2025

Joshua Richter, MD, discusses the exploration of CELMoDs in the treatment of patients with multiple myeloma.

FDA Grants Accelerated Approval to Sevabertinib in HER2-Mutated Nonsquamous NSCLC

November 19th 2025

The FDA approved sevabertinib for previously treated, nonsquamous non–small cell lung cancer with HER2 TKD activating mutations.

Modified Daratumumab-Based Quadruplet Shows Feasibility in Older Multiple Myeloma

November 19th 2025

Andrew Yee, MD, discusses data for a modified four-drug regimen studied in older patients with newly diagnosed multiple myeloma.

European Commission Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma

November 19th 2025

The European Commission has approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma.

FDA Approves Selumetinib for Adult NF1-Associated Plexiform Neurofibromas

November 19th 2025

The FDA approved selumetinib for the treatment of adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Dr Herzberg on Management Challenges in STK11/KEAP1+, SMARCA4-Deficient Undifferentiated Tumors and NUT Carcinoma

November 18th 2025

Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.

Dr Masserelli on the Clinical Presentation and Management of LEMS in SCLC

November 18th 2025

Erminia Massarelli, MD, PhD, MS, discusses the clinical presentation and management of Lambert–Eaton myasthenic syndrome in the context of small cell lung cancer.

FDA Awards Orphan Drug Designation to ZEN-3694 for NUT Carcinoma

November 18th 2025

ZEN-3694 obtained orphan drug designation from the FDA for the treatment of NUT carcinoma.

FDA Grants Fast Track Designation to FOG-001 for Desmoid Tumors

November 14th 2025

The FDA granted fast track designation to FOG-001 for the treatment of patients with desmoid tumors.

PSMAddition Data Support Integration of Lutetium Lu 177 Vipivotide Tetraxetan into mHSPC Management

November 14th 2025

Scott Tagawa, MD, MS, FACP, FASCO, discusses data for lutetium Lu 177 vipivotide tetraxetan in mHSPC from the PSMAddition trial.

FDA Approves New Pertuzumab Biosimilar for Select HER2+ Breast Cancer Subtypes

November 13th 2025

The FDA has approved pertuzumab-dpzb as the first interchangeable biosimilar for pertuzumab across several indications in HER2-positive breast cancer.

FDA Grants 510(k) Clearance to EXENT System for Multiple Myeloma Diagnosis

November 13th 2025

The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.